Mast cell leukemia pathophysiology

Mast cell leukemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Mast cell leukemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Mast cell leukemia pathophysiology On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Mast cell leukemia pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Mast cell leukemia pathophysiology
CDC on Mast cell leukemia pathophysiology
Mast cell leukemia pathophysiology in the news
Blogs on Mast cell leukemia pathophysiology
Directions to Hospitals Treating Mast cell leukemia
Risk calculators and risk factors for Mast cell leukemia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

Immunohistochemistry

• Atypical mast cells express multiple surface antigens such as:

• CD117/kit

• CD11c

• CD13

• CD29

• CD33

• CD44

• CD45

• CD63

• CD68

• CD71

• CD2

• CD22

• CD25

• CD54

• The role of these antigens is however not yet understood.

• CD2 and CD25 antigens are important markers and their positivity on the surface of mast cells constitute minor criteria for the diagnosis of mast cell disease.